The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors.

Compared with the use of SGLT2 inhibitors, the use of GLP-1 receptor agonists and DPP-4 inhibitors was associated with a similar risk for acute pancreatitis (hazard ratio [HR], 1.01; 95% CI, 0.90-1.13 ...

Scientists have discovered another benefit of the blockbuster weight-loss and blood-glucose-lowering drug semaglutide, known as Ozempic and Wegovy, which could improve the lives of 38 million diabetic ...

HONOLULU (HawaiiNewsNow) - The Honolulu Department of Planning and Permitting announced the launch of CivCheck, a free new artificial intelligence software designed to help prepare permit applications ...

Aché Laboratórios Farmacêuticos SA has identified compounds acting as sodium/glucose cotransporter 1 (SGLT-1), SGLT-2 and dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the ...